
Drug from Novartis reduces the risk of recurrence in early-stage breast cancer by 25%.
Frankfurt: In a pivotal trial on women with early-stage breast cancer, Novartis' Kisqali reduced the risk of recurrence by more than 25%, putting the Swiss pharmaceutical company in a good position to attract new patients, but Eli Lilly remained a …